128 related articles for article (PubMed ID: 34536930)
1. Synthesis and biological assessment of new pyrimidopyrimidines as inhibitors of breast cancer resistance protein (ABCG2).
Dakhlaoui I; Vahdati S; Maalej E; Chabchoub F; Wiese M; Marco-Contelles J; Ismaili L
Bioorg Chem; 2021 Nov; 116():105326. PubMed ID: 34536930
[TBL] [Abstract][Full Text] [Related]
2. Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
Silbermann K; Li J; Namasivayam V; Stefan SM; Wiese M
Eur J Med Chem; 2021 Feb; 212():113045. PubMed ID: 33454462
[TBL] [Abstract][Full Text] [Related]
3. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
4. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
[TBL] [Abstract][Full Text] [Related]
5. Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2.
Guragossian N; Belhani B; Moreno A; Nunes MT; Gonzalez-Lobato L; Marminon C; Berthier L; Rocio Andrade Pires AD; Özvegy-Laczka C; Sarkadi B; Terreux R; Bouaziz Z; Berredjem M; Jose J; Di Pietro A; Falson P; Le Borgne M
Eur J Med Chem; 2021 Feb; 211():113017. PubMed ID: 33223263
[TBL] [Abstract][Full Text] [Related]
6. New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
Krapf MK; Gallus J; Vahdati S; Wiese M
J Med Chem; 2018 Apr; 61(8):3389-3408. PubMed ID: 29547272
[TBL] [Abstract][Full Text] [Related]
7. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
Vesga LC; Kronenberger T; Tonduru AK; Kita DH; Zattoni IF; Bernal CC; Bohórquez ARR; Mendez-Sánchez SC; Ambudkar SV; Valdameri G; Poso A
ChemMedChem; 2021 Sep; 16(17):2686-2694. PubMed ID: 33844464
[TBL] [Abstract][Full Text] [Related]
9. Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
Roussel E; Moréno A; Altounian N; Philouze C; Pérès B; Thomas A; Renaudet O; Falson P; Boumendjel A
Eur J Med Chem; 2020 Sep; 202():112503. PubMed ID: 32653696
[TBL] [Abstract][Full Text] [Related]
10. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
11. Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
Cai CY; Zhai H; Lei ZN; Tan CP; Chen BL; Du ZY; Wang JQ; Zhang YK; Wang YJ; Gupta P; Wang B; Chen ZS
Eur J Med Chem; 2019 Oct; 179():849-862. PubMed ID: 31302589
[TBL] [Abstract][Full Text] [Related]
12. Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists.
Silbermann K; Li J; Namasivayam V; Baltes F; Bendas G; Stefan SM; Wiese M
J Med Chem; 2020 Sep; 63(18):10412-10432. PubMed ID: 32787102
[TBL] [Abstract][Full Text] [Related]
13. An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms.
Zeng L; Li J; Zhang C; Zhang YK; Zhang W; Huang J; Ashby CR; Chen ZS; Chao H
Chem Commun (Camb); 2019 Mar; 55(26):3833-3836. PubMed ID: 30869688
[TBL] [Abstract][Full Text] [Related]
14. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
15. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
Silbermann K; Shah CP; Sahu NU; Juvale K; Stefan SM; Kharkar PS; Wiese M
Eur J Med Chem; 2019 Feb; 164():193-213. PubMed ID: 30594677
[TBL] [Abstract][Full Text] [Related]
16. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
17. A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.
Strouse JJ; Ivnitski-Steele I; Khawaja HM; Perez D; Ricci J; Yao T; Weiner WS; Schroeder CE; Simpson DS; Maki BE; Li K; Golden JE; Foutz TD; Waller A; Evangelisti AM; Young SM; Chavez SE; Garcia MJ; Ursu O; Bologa CG; Carter MB; Salas VM; Gouveia K; Tegos GP; Oprea TI; Edwards BS; Aubé J; Larson RS; Sklar LA
J Biomol Screen; 2013 Jan; 18(1):26-38. PubMed ID: 22923785
[TBL] [Abstract][Full Text] [Related]
18. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
19. Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Hsiao SH; Murakami M; Lu MJ; Li YQ; Hsieh CH; Ambudkar SV; Wu YS
Cancer Lett; 2017 Nov; 409():56-65. PubMed ID: 28893612
[TBL] [Abstract][Full Text] [Related]
20. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
